ArticleInfection and drug resistance2026
Risk Factors for Subtherapeutic Exposure and Hepatotoxicity Threshold of Posaconazole: A Real-World Study in Chinese Patients with Invasive Pulmonary Fungal Infection.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posaconazole exhibits substantial pharmacokinetic variability, particularly with oral formulations. Real-world data on target attainment across formulations and on specific toxicity thresholds remain limited. This study aimed to evaluate posaconazole target attainment rates, identify independent predictors of subtherapeutic exposure, and explore potential hepatotoxicity exposure thresholds in a real-world Chinese cohort. Methods: This single-centre, retrospective observational study conducted at Nanjing Drum Tower Hospital, China, between January 2023 and August 2025 enrolled 148 patients with IPFI. Posaconazole was administered for prophylaxis with a target trough concentration of ≥0.5 mg/L, or for treatment with a target of ≥1.0 mg/L. Multivariable logistic regression was utilised to identify independent predictors of subtherapeutic exposure. Results: Subtherapeutic trough concentrations were observed in 24.0% of the prophylaxis group and 23.3% of the treatment group. Concomitant proton pump inhibitor (PPI) use was the dominant independent risk factor for subtherapeutic exposure in both prophylaxis (OR 17.97, 95% CI 4.22-76.53, Conclusion: Subtherapeutic posaconazole exposure remains common. PPI use is a critical risk factor that may not be fully overcome by delayed-release or intravenous formulations. Our findings suggest a potential exposure-hepatotoxicity relationship around 1.95 mg/L for Chinese patients, highlighting the need for individualised TDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.